GlassScriptPhysician profile
Matthew L Stolz
NPI 1548690969
$9,545.08
in general payments reported to CMS, 2019-2025
27 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $330 · 2021: $1,050 · 2022: $817 · 2023: $1,357 · 2024: $3,864 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,894 · Travel and Lodging: $1,662 · Entertainment: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.65 |
| Travel and Lodging | $1,662.30 |
| Entertainment | $174.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,676.15 | 2021-2025 | |
| Alcon Vision LLC | $1,754.75 | 2019-2025 | Rocklatan, Total30, Clareon |
| Sun Pharmaceutical Industries INC. | $669.20 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $574.52 | 2019-2021 | |
| Dompe US, INC. | $530.92 | 2021-2025 | Oxervate |
| Rxsight INC | $424.47 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $390.97 | 2022-2025 | Omni Surgical System, Tearcare System |
| Oyster Point Pharma, INC. | $371.84 | 2023-2025 | Tyrvaya |
| Coopervision INC. | $353.81 | 2021-2025 | Myday Contact Lens, Misight Contact Lens, Synergeyes Contact Lens |
| Optos, INC. | $271.17 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $190.99 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $150.87 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $136.34 | 2021-2023 | Tepezza |
| Abbvie INC. | $124.27 | 2022-2024 | Lumigan, Durysta |
| Apellis Pharmaceuticals, INC. | $121.84 | 2024 | Syfovre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $120.66 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Shire North American Group INC | $114.94 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $107.50 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $92.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.59 | 2020-2023 | |
| Allergan, INC. | $68.07 | 2020-2021 | |
| Harrow Eye, LLC | $64.62 | 2024 | Vevye |
| Merz Pharmaceuticals, LLC | $61.62 | 2023-2024 | Xeomin |
| Kala Pharmaceuticals, INC. | $38.85 | 2022 | |
| Amgen INC. | $27.28 | 2024 | Tepezza |
| Glaukos Corporation | $18.19 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.11 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stolz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.